Mereo BioPharma (MREO) Assets (2017 - 2026)

Mereo BioPharma (MREO) has 10 years of Assets data on file, last reported at $40.6 million in Q1 2026.

• Assets for Q1 2026 came in at $40.6 million, down 40.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $40.6 million (down 40.56% YoY), and the FY2025 annual result was $45.9 million, down 39.89% from the prior year.
• Assets slipped to $40.6 million in Q1 2026 per MREO's latest filing, from $45.9 million in the prior quarter.
• Over five years, Assets peaked at $103.3 million in Q4 2022 and troughed at $40.6 million in Q1 2026.
• A 5-year average of $68.9 million and a median of $66.5 million in 2023 frame the typical range for Assets.
• The sharpest annual moves came in 2025 and 2026: Assets grew 22.14% in 2025, then slumped 40.56% in 2026.
• A 5-year view of Assets shows it stood at $103.3 million in 2022, then sank by 35.63% to $66.5 million in 2023, then gained by 14.87% to $76.4 million in 2024, then plunged by 39.89% to $45.9 million in 2025, then retreated by 11.55% to $40.6 million in 2026.
• Business Quant data shows MREO's Assets at $40.6 million in Q1 2026, $45.9 million in Q4 2025, and $53.6 million in Q3 2025.